InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Couch post# 277133

Monday, 10/24/2016 8:58:39 PM

Monday, October 24, 2016 8:58:39 PM

Post# of 345786
I will take a good old fashioned type of partnership also.. If SK and Peregrine thinks it will not hold back PS Targeting but I wonder why Abbvie picked up Stemcentrx for $10.2 Billion when Garnick was involved and anyone get the feeling that something is heading Peregrines way?

Partnership with upfront money I can see in the future. Peter Thiel can push things along if he wanted to...


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News